Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide

Genevieve M. Weir1*, Olga Hrytsenko1, Tara Quinton1, Neil L. Berinstein2,3, Marianne M. Stanford1,4 and Marc Mansour1 1 Immunovaccine Inc., 1344 Summer St., Halifax, NS B3H 0A8, Canada. 2 Sunnybrook Research Institute, 2075 Bayview Ave., Toronto, ON M4N 3M5, Canada. 3 University of Toronto, 27 King’s College Cir, Toronto, ON M5S 1A1, Canada. 4 Department of Microbiology & Immunology, Dalhousie University, 5850 College St., Room 7C, Halifax, NS B3H 4R2, Canada.